FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease

  Global Blood Therapeutics, Inc. announced only a few hours ago that the U.S. Food and Drug Ad...

TIF by the side of thalassaemia patients in Syria

  The World Health Organisation (WHO) has contacted the Thalassaemia International Federation (...

      IS BETA – THALASSAEMIA OR SICKLE CELL DISEASE IN YOUR PIPELINE?   LEARN ABOUT PATIENTS’ EXPECT...

TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries

A new and encouraging chapter is finally opening up for patients with thalassaemia, following the re...

New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019

  Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are e...